StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Item 2(c) / Item 5 by Quarter

Item 2(c) / Item 5 — Shares purchased under publicly announced programs in quarter (thousands)

Vertex Pharmaceuticals Item 2(c) / Item 5: 1,033.70K in Q2 2026, up 19.0% from a year earlier.

Latest, Q2 2026
1,033.70
Period ended Jun 30, 2026
Change on a year earlier
+19.0%
868.70 in Q2 2025
History
27 quarters
Since Q1 2018
Sources
27
Documents cited below

Where the Q2 2026 figure comes from

“|| Total | 1,033,652 | $ 440.17 | 1,033,652 | $ 2,582,008,580”

Source: Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗

Reported in Form 10-Q Part II Item 2(c) & Form 10-K Item 5.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedItem 2(c) / Item 5 — Shares purchased under publicly announced programs in quarter (thousands)Year on yearSource
Q2 2026Jun 30, 20261,033.70+19.0%Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026741.10-20.5%Form 10-Q (vrtx-20260331.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025256.80-73.3%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Q3 2025Sep 30, 20252,728.20+326.3%Form 10-Q (vrtx-20250930.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 2025868.70+18.0%Form 10-Q (vrtx-20250630.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 2025932.50+177.7%Form 10-Q (vrtx-20250331.htm, filed 2025-05-06) ↗
Q4 2024Dec 31, 2024961.10+141.5%Form 10-K (vrtx-20241231.htm, filed 2025-02-13) ↗
Q3 2024Sep 30, 2024640.00+81.5%Form 10-Q (vrtx-20240930.htm, filed 2024-11-05) ↗
Q2 2024Jun 30, 2024736.00+825.8%Form 10-Q (vrtx-20240630.htm, filed 2024-08-02) ↗
Q1 2024Mar 31, 2024335.80-26.8%Form 10-Q (vrtx-20240331.htm, filed 2024-05-07) ↗
Q4 2023Dec 31, 2023398.00–Form 10-K (vrtx-20231231.htm, filed 2024-02-15) ↗
Q3 2023Sep 30, 2023352.60–Form 10-Q (vrtx-20230930.htm, filed 2023-11-07) ↗
Q2 2023Jun 30, 202379.50–Form 10-Q (vrtx-20230630.htm, filed 2023-08-02) ↗
Q1 2023Mar 31, 2023459.00–Form 10-Q (vrtx-20230331.htm, filed 2023-05-02) ↗
Q4 2021Dec 31, 20211,986.00+231.9%Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗
Q3 2021Sep 30, 20213,293.20+717.8%Form 10-Q (vrtx-20210930.htm, filed 2021-11-03) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Item 2(c) / Item 5, quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/qtr-buyback-prog-sh

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.